ASRS 2023: Michael Ip, MD, on key trends and perspectives from the 2023 meeting in Seattle

Michael Ip, MD, shared his perspective on the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event, including dry age-related macular degeneration (AMD) and the future of gene therapy.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Michael Ip, MD:

Hello, this is Michael Ip at the ASRS meeting in Seattle, Washington. I have been asked to describe what I think is actually the most important and some of the most interesting topics that have, so far, been presented. And I think it's been a very fascinating meeting. I think there's been a lot going on in the field. From what I can see right now, some of the most interesting topics that have been presented, regard are treatments for dry age-related macular degeneration, many of the treatments seem to be very effective. We are now grappling with some of the potential downsides to some of the side effects.

Earlier this morning, there were several presentations on this topic, and, despite a lot of the enthusiasm that we've had for some of these therapies, I think we now have to temper some of our enthusiasm and follow some of these patients, see ultimately what some of these outcomes are.

Other things that have been very interesting with regards to what's going on at this meeting have been some of the gene therapy treatments that have been out there. The gene therapy, treatments range everything from treatment of diabetic retinopathy to neovascular, age-related macular degeneration, as well as complement inhibition, with a gene therapy approach for dry age-related macular degeneration. So, these are some of the things that are being focused on at the current ASRS, and I think we will be talking about them for many years to come. So thank you.